News

The therapy showed significant efficacy in a Phase 3 trial and may be more difficult for variants to develop a resistance against.

The investigators plan to continue testing their method with the ultimate goal of developing a free online platform for medical image classification.

People who experienced COVID-19 symptoms and had the virus in their saliva were more likely to report loss of taste and smell, suggesting that oral infection might underlie oral symptoms.

The companies announced they are expanding their study in children ages 6 months to 11 years old.

Spero Therapeutics expects to submit a new drug application this year for Tebipenem HBr, the first oral carbapenem for treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis (AP).

The phase 2b-3 trial analyzing the efficacy of the ALVAC–gp120 regimen showed that it did not prevent an HIV-1 infection among the participants in the study at 24 months.

The president updated his goal during his press conference this afternoon.

The study also provided insight into potential differences between the immune response elicited by the two mRNA vaccines created by Pfizer and Moderna.

Tilorone, quinacrine and pyronaridines effectiveness depended on whether they were used in human-derived cell lines or monkey derived cell lines.

Overnight, the company restated it had a 76% efficacy against symptomatic disease and is looking to file an Emergency Use Authorization (EUA) with the Food and Drug Administration (FDA).

Survivors of the disease have been found to be at an increased risk of blood clots or strokes due to a prolonged immune response caused by the virus.

More respondents with an infection reported daily burnout than those who did not have one.

People who received their vaccine were also significantly less likely to require hospitalization.

Long-acting injectables for latent and active tuberculous (TB) might be a treatment option in the future and could open up the door to possibly bundling HIV and TB care together.

To mark World TB Day, a pair of experts break down the currently defined regimens for latent and active tuberculosis—and what may still come.

A statement hours after the company reported promising interim phase 3 data stated the Data Safety and Monitoring Board believes they included outdated data “which may have provided an incomplete view of the efficacy data.”

Filmmaker Bill Mudge has released his new documentary, Beating Superbugs: Can We Win? It looks at emerging technologies designed to develop new therapies to combat antibiotic resistance (ABR).

Levels of interferon gene activity were much lower in those with the missense mutation.

Regeneron announces results from Phase 3 trial of its monoclonal antibody treatment.

The challenges of explaining new guidance, like that for school-aged children, is so important to ensure people understand the science and reasoning behind it, but also why following it is important.

Facilities in Connecticut had an outbreak prior to vaccinating their residents, which in turn controlled the spread effectively.

Reproduction number should govern allocation of the shot, researchers say.

New polls shows confidence in AstraZeneca vaccine plummets in Europe.

The small country's emphasis on accessible testing provided more up-to-date tracking, and opportunity for research into reinfection risk.

After a year of setbacks, AZD1222 has been associated with 100% prevention of severe COVID-19 in US trial participants. Could emergency authorization come soon?

An interview on perspectives learned from a nationwide PCR test database assessment.

The Infectious Diseases Society of America (IDSA) discusses some of the new treatments show measurable impact on severe disease and death.

8% of ischemic stroke patients had atrial fibrillation, while 9% of those without stroke also had atrial fibrillation.